TABLE 4.

Subgroup analysis for the association of sRAGE and the risk of mortality¹

Variables	Number of effect measures	I2	Effect measures (95% CI)	P value 2
All-cause mortality
Overall	16	75.5	1.01 (1.00, 1.01)	0.205
Health status
DM or renal dysfunction	10	76.7	1.00 (1.00, 1.01)	0.209
Without DM or renal dysfunction	6	74.5	1.00 (0.99, 1.00)
Follow-up duration
≤6 y	8	77.7	1.00 (1.00,1.01)	0.240
>6 y	8	74.2	1.00 (0.99, 1.00)
Participants’ age
<60 y	6	84.8	0.99 (0.99, 1.00)	0.016
≥60 y	10	59.1	1.00 (1.00, 1.01)
CVD mortality
Overall	7	78.9	1.02 (1.00, 1.04)	0.020
Health status
DM or renal dysfunction	2	89.7	1.02 (1.01, 1.03)	0.190
Without DM or renal dysfunction	5	76.5	1.01 (1.00, 1.02)
Follow-up duration
≤6 y	3	81.8	1.01 (1.00, 1.03)	0.734
>6 y	4	82.7	1.01 (1.00, 1.02)

¹CVD, cardiovascular disease; DM, diabetes mellitus; sRAGE, soluble receptor for advanced glycation end products.

²P value for overall effect and subgroup differences